Trial Profile
Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2019
Price :
$35
*
At a glance
- Drugs AV 101 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms ELEVATE
- Sponsors VistaGen Therapeutics
- 14 Nov 2019 According to a VistaGen Therapeutics media release, the company will continue to examine the full dataset from this study to evaluate effects on other endpoints and pharmacokinetics.
- 14 Nov 2019 Topline results presented in a VistaGen Therapeutics media release.
- 08 Oct 2019 According to a VistaGen Therapeutics media release, the company announced that the last patient has completed the dosing. The company remains on track to report the top line results of this study before the end of 2019.